Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2026
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.
Journal: Leukemia & lymphoma
Published: July 02, 2025
Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.
Journal: British journal of haematology
Published: February 20, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
Journal: Leukemia & lymphoma
Published: February 08, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.
Journal: Haematologica
Published: January 11, 2025
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 11, 2024
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
Journal: Leukemia & lymphoma
Published: September 20, 2024
Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Journal: Haematologica
Published: August 01, 2024
Last Updated: 09/26/2026